-DOCSTART- -X- O
Nipah -X- _ O
virus -X- _ O
( -X- _ O
NiV -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
highly -X- _ O
pathogenic -X- _ O
re-emerging -X- _ O
virus -X- _ O
that -X- _ O
causes -X- _ O
outbreaks -X- _ O
in -X- _ O
South -X- _ O
East -X- _ O
Asia. -X- _ O
Currently -X- _ O
, -X- _ O
no -X- _ O
approved -X- _ O
and -X- _ O
licensed -X- _ O
vaccine -X- _ O
or -X- _ O
antivirals -X- _ O
exist. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
investigated -X- _ O
the -X- _ O
efficacy -X- _ O
of -X- _ O
ChAdOx1 -X- _ B-Intervention
NiV -X- _ I-Intervention
( -X- _ I-Intervention
B -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
a -X- _ O
simian -X- _ O
adenovirus-based -X- _ O
vaccine -X- _ O
encoding -X- _ O
NiV -X- _ O
glycoprotein -X- _ O
( -X- _ O
G -X- _ O
) -X- _ O
Bangladesh -X- _ O
, -X- _ O
in -X- _ O
Syrian -X- _ B-Patient
hamsters. -X- _ I-Patient
Prime-only -X- _ B-Outcome
as -X- _ I-Outcome
well -X- _ I-Outcome
as -X- _ I-Outcome
prime-boost -X- _ I-Outcome
vaccination -X- _ I-Outcome
resulted -X- _ I-Outcome
in -X- _ I-Outcome
uniform -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
a -X- _ I-Outcome
lethal -X- _ I-Outcome
challenge -X- _ I-Outcome
with -X- _ I-Outcome
NiV -X- _ I-Outcome
Bangladesh -X- _ I-Outcome
: -X- _ I-Outcome
all -X- _ I-Outcome
animals -X- _ I-Outcome
survived -X- _ I-Outcome
challenge -X- _ I-Outcome
and -X- _ I-Outcome
we -X- _ I-Outcome
were -X- _ I-Outcome
unable -X- _ I-Outcome
to -X- _ I-Outcome
find -X- _ I-Outcome
infectious -X- _ I-Outcome
virus -X- _ I-Outcome
either -X- _ I-Outcome
in -X- _ I-Outcome
oral -X- _ I-Outcome
swabs -X- _ I-Outcome
, -X- _ I-Outcome
lung -X- _ I-Outcome
or -X- _ I-Outcome
brain -X- _ I-Outcome
tissue. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
no -X- _ I-Outcome
pathological -X- _ I-Outcome
lung -X- _ I-Outcome
damage -X- _ I-Outcome
was -X- _ I-Outcome
observed. -X- _ I-Outcome
A -X- _ I-Outcome
single-dose -X- _ I-Outcome
of -X- _ I-Outcome
ChAdOx1 -X- _ I-Outcome
NiV -X- _ I-Outcome
( -X- _ I-Outcome
B -X- _ I-Outcome
) -X- _ I-Outcome
also -X- _ I-Outcome
prevented -X- _ I-Outcome
disease -X- _ I-Outcome
and -X- _ I-Outcome
lethality -X- _ I-Outcome
from -X- _ I-Outcome
heterologous -X- _ I-Outcome
challenge -X- _ I-Outcome
with -X- _ I-Outcome
NiV -X- _ I-Outcome
Malaysia. -X- _ I-Outcome
While -X- _ I-Outcome
we -X- _ I-Outcome
were -X- _ I-Outcome
unable -X- _ I-Outcome
to -X- _ I-Outcome
detect -X- _ I-Outcome
infectious -X- _ I-Outcome
virus -X- _ I-Outcome
in -X- _ I-Outcome
swabs -X- _ I-Outcome
or -X- _ I-Outcome
tissue -X- _ I-Outcome
of -X- _ I-Outcome
animals -X- _ I-Outcome
challenged -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
heterologous -X- _ I-Outcome
strain -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
very -X- _ I-Outcome
limited -X- _ I-Outcome
amount -X- _ I-Outcome
of -X- _ I-Outcome
viral -X- _ I-Outcome
RNA -X- _ I-Outcome
could -X- _ I-Outcome
be -X- _ I-Outcome
found -X- _ I-Outcome
in -X- _ I-Outcome
lung -X- _ I-Outcome
tissue -X- _ I-Outcome
by -X- _ I-Outcome
in -X- _ I-Outcome
situ -X- _ I-Outcome
hybridization. -X- _ I-Outcome
A -X- _ I-Outcome
single -X- _ I-Outcome
dose -X- _ I-Outcome
of -X- _ I-Outcome
ChAdOx1 -X- _ I-Outcome
NiV -X- _ I-Outcome
( -X- _ I-Outcome
B -X- _ I-Outcome
) -X- _ I-Outcome
also -X- _ I-Outcome
provided -X- _ I-Outcome
partial -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
Hendra -X- _ I-Outcome
virus -X- _ I-Outcome
and -X- _ I-Outcome
passive -X- _ I-Outcome
transfer -X- _ I-Outcome
of -X- _ I-Outcome
antibodies -X- _ I-Outcome
elicited -X- _ I-Outcome
by -X- _ I-Outcome
ChAdOx1 -X- _ I-Outcome
NiV -X- _ I-Outcome
( -X- _ I-Outcome
B -X- _ I-Outcome
) -X- _ I-Outcome
vaccination -X- _ I-Outcome
partially -X- _ I-Outcome
protected -X- _ I-Outcome
Syrian -X- _ I-Outcome
hamsters -X- _ I-Outcome
against -X- _ I-Outcome
NiV -X- _ I-Outcome
Bangladesh. -X- _ I-Outcome
From -X- _ O
these -X- _ O
data -X- _ O
, -X- _ O
we -X- _ O
conclude -X- _ O
that -X- _ O
ChAdOx1 -X- _ B-Outcome
NiV -X- _ I-Outcome
( -X- _ I-Outcome
B -X- _ I-Outcome
) -X- _ I-Outcome
is -X- _ I-Outcome
a -X- _ I-Outcome
suitable -X- _ I-Outcome
candidate -X- _ I-Outcome
for -X- _ I-Outcome
further -X- _ I-Outcome
NiV -X- _ I-Outcome
vaccine -X- _ I-Outcome
pre-clinical -X- _ I-Outcome
development -X- _ I-Outcome
. -X- _ O

